Pharmaceutical Regulation and Compliance in the GCC

The Gulf Cooperation Council (GCC) pharmaceutical market is valued at over USD 40 billion and is projected to grow at a compound annual growth rate of 7–9 per cent through 2030. This growth is driven by population expansion, rising chronic disease prevalence, government-led healthcare modernisation (e.g., Saudi Vision 2030, UAE We the UAE 2031), and a regional push toward domestic pharmaceutical manufacturing. However, the regulatory environment remains fragmented and exacting. Each member state operates its own drug regulatory authority while participating in varying degrees of GCC-level harmonisation.

For pharmaceutical companies seeking to register products, manufacture locally, conduct clinical trials, or market across the region, compliance is a high-stakes exercise. This guide provides a comprehensive overview of pharmaceutical regulation in the GCC, covering drug authorities by country, drug registration pathways, Good Manufacturing Practice (GMP) requirements, pharmacovigilance obligations, pricing and reimbursement controls, advertising restrictions, import/export controls, and clinical trial regulation.

Drug Regulatory Authorities by Country

Pharmaceutical regulation in the GCC is distributed across six national authorities, with the GCC Executive Board for Health Ministers (GCC-HEM) promoting harmonisation through the GCC Central Drug Registration (GCC-DR) initiative.

The GCC-DR was established to allow a single registration dossier to be reviewed once and accepted across all participating states. In practice, full harmonisation remains aspirational. Each country retains the right to conduct its own review, request additional data, and make independent approval decisions. However, products approved through the GCC-DR pathway benefit from accelerated review timelines in most member states.

Drug Registration Pathways

Pharmaceutical products must be registered with the competent authority in each country where they will be marketed. The registration process follows a standardised modular dossier structure aligned with the Common Technical Document (CTD) format.

Registration Timelines and Fees

All GCC authorities require a valid Certificate of a Pharmaceutical Product (CPP) from the country of origin, issued by the relevant national drug authority. For generic products, bioequivalence studies conducted at approved GCC centres are mandatory. Biologics and biosimilars face additional submission requirements, including comparability protocols and risk-management plans.

Good Manufacturing Practice (GMP) Requirements

GMP compliance is a prerequisite for pharmaceutical manufacturing and importation across the GCC. All manufacturing sites—whether local or foreign—must hold a GMP certificate issued by a competent authority recognised by the importing GCC state.

The SFDA and MOHAP conduct their own GMP inspections of foreign manufacturing sites. The SFDA in particular has significantly expanded its international inspection programme, conducting on-site audits in India, China, Europe, and the Americas. A site that has not been inspected by the SFDA may still be accepted if it holds a GMP certificate from a stringent regulatory authority (SRA) such as the EMA, FDA, MHRA, or TGA. However, the SFDA retains the right to request a desk-top assessment or a joint inspection.

Key GMP requirements applied in the GCC include:

• Compliance with PIC/S Guide to GMP (all GCC members except Bahrain are PIC/S members)
• Stability testing under GCC climatic zone IVa conditions (hot and humid)
• Product quality review (PQR) documentation
• Validation master plan covering process, cleaning, and analytical methods
• Recall capability and mock recall exercises

Manufacturers seeking to supply the GCC market should factor GMP inspection lead times into their market-access timeline. An SFDA inspection can take 6 to 12 months to schedule from the date of application.

Pharmacovigilance

Pharmacovigilance (PV) systems in the GCC have matured rapidly over the past decade. All member states now require marketing authorisation holders (MAHs) to maintain a local PV system and appoint a Qualified Person for Pharmacovigilance (QPPV) resident in or accessible to the country.

PV Obligations by Country

The SFDA was the first GCC authority to mandate electronic submission of individual case safety reports (ICSRs) via the EudraVigilance format. The UAE and Qatar are moving toward the same standard. MAHs should ensure that their PV database can transmit ICSRs in ICH E2B(R3) format.

Pricing and Reimbursement

Drug pricing is regulated across the GCC. Each country sets maximum ex-factory and retail prices, and manufacturers cannot freely determine market prices.

• Saudi Arabia – SFDA sets ceiling prices based on reference pricing from selected countries (e.g., UK, Australia, South Korea). The “external reference pricing” model is applied systematically. Prices are typically reduced by 20–40 per cent compared to originator-country prices.
• UAE – MOHAP sets maximum consumer prices. The UAE previously used a cost-plus model but is transitioning to reference pricing. Free-zone pharmacies may operate under different pricing rules.
• Qatar, Kuwait, Oman, Bahrain – Each country applies its own pricing formula, typically referencing SFDA-approved prices and international benchmarks.

Reimbursement is determined at the payer level. In Saudi Arabia, the Council of Health Insurance (CHI) manages the drug formulary for the private insurance sector, while the Saudi Health Council oversees the public formulary. In the UAE, the national payor (mainly DHA in Dubai, DoH in Abu Dhabi, and private insurers elsewhere) maintains separate formularies. Listing on the national formulary is essential for market access, as out-of-pocket spend is low for prescription medicines.

Advertising and Promotion

Pharmaceutical advertising is heavily regulated across the GCC. Prescription medicines and controlled substances cannot be advertised to the general public. Over-the-counter (OTC) products may be advertised subject to prior approval of all promotional materials.

Key advertising restrictions include:

• Mandatory submission of all advertisements to the SFDA or MOHAP for pre-approval (validity 1–2 years)
• No comparative claims against competitor products unless supported by head-to-head clinical data
• No use of terms such as “safe,” “no side effects,” or “guaranteed” without qualification
• No direct-to-consumer advertising of products containing controlled ingredients
• All claims must be substantiated by references submitted with the application

Digital promotion (social media, influencer marketing, search advertising) is subject to the same rules. The SFDA has issued specific guidance on social media promotion, requiring that all sponsored content be identifiable as advertising and pre-approved in the same manner as traditional media.

Import and Export Controls

Pharmaceutical importation is restricted to licensed importers. Each shipment must be accompanied by a permit or import release from the national drug authority. Controlled substances (narcotics, psychotropics) require additional permits from the national narcotics control authority and, in some cases, the Ministry of Interior.

Export of pharmaceutical products from GCC countries is generally less restricted than import, but exported products must comply with the destination country’s requirements. The SFDA and MOHAP issue export certificates for pharmaceutical products to facilitate trade with non-GCC markets.

Clinical Trials Regulation

Clinical trial regulation in the GCC has been modernised significantly, with Saudi Arabia, the UAE, and Qatar emerging as regional clinical research hubs.

• Saudi Arabia – The SFDA’s National Committee for Drugs and Medical Devices (NCB) oversees clinical trial authorisation. The timeline is 30–90 days for review. Mandatory registration on the Saudi Clinical Trials Registry is required.
• UAE – Clinical trials are regulated by MOHAP (federal) and by local authorities in Dubai (DHA) and Abu Dhabi (DoH). The review timeline is 60–120 days. The UAE Clinical Trials Registry is mandatory.
• Qatar – MoPH authorises clinical trials with a review timeline of 30–90 days. Qatar has invested heavily in clinical research infrastructure through Qatar Foundation and Sidra Medicine.
• Kuwait, Oman, Bahrain – Clinical trial activity is lower but growing. Each country requires local regulatory approval, ethics committee clearance, and compliance with ICH GCP guidelines.

All GCC countries require that clinical trial sponsors have liability insurance, that trial sites have GCP-trained investigators, and that the trial is conducted in compliance with the Declaration of Helsinki.

Frequently Asked Questions

1. Can a product registered in one GCC country be sold in another without additional registration?

No. Despite the GCC-DR initiative, each country still requires separate registration. A product approved through GCC-DR may receive an accelerated review, but separate marketing authorisations must still be obtained from each national authority.

2. What are the GMP requirements for a manufacturer outside the GCC?

Foreign manufacturers must hold a GMP certificate from a competent authority recognised by the importing GCC country. The SFDA and MOHAP may also conduct their own on-site inspections. Manufacturers regulated by an SRA (e.g., EMA, FDA) generally find a faster pathway, but this does not exempt them from local registration requirements.

3. How long is a pharmaceutical product registration valid?

In most GCC countries, product registration is valid for 5 years and must be renewed before expiry. Renewal requires submission of updated quality, safety, and efficacy data, including all PSURs submitted during the registration period.

4. Are biosimilars regulated differently from small-molecule generics?

Yes. Biosimilars face additional regulatory requirements, including comparability exercises against the reference biologic, immunogenicity studies, and a risk-management plan. The SFDA and MOHAP have issued specific biosimilar guidelines aligned with WHO recommendations, but they have not yet adopted abbreviated biosimilar pathways.

5. What are the penalties for non-compliance with pharmaceutical advertising rules?

Penalties vary by country but can include fines of up to SAR 1 million in Saudi Arabia, suspension of the product registration, and blacklisting of the advertising agency. In the UAE, fines range from AED 50,000 to AED 500,000, with repeat offenders facing licence revocation.

6. Can a foreign company sponsor a clinical trial in the GCC?

Yes, but the foreign sponsor must appoint a local legal representative or contract research organisation (CRO) that holds the necessary licences. The sponsor must also comply with local data protection requirements, particularly in Saudi Arabia (PDPL) and the UAE (Federal Decree-Law No. 45 of 2021).

How Bitrixme Can Help

Pharmaceutical compliance in the GCC demands deep regulatory knowledge, meticulous dossier preparation, and ongoing vigilance across multiple jurisdictions. Bitrixme’s life sciences compliance consultants offer end-to-end support, from drug registration strategy and GMP inspection preparation to pharmacovigilance system setup and clinical trial authorisation.

Contact Bitrixme for a pharmaceutical market-access assessment tailored to your product portfolio and target GCC markets.